Par Pharmaceutical Inc.

Par Pharmaceutical Inc. is a pharmaceutical company founded in 1978, known for developing, manufacturing, and distributing generic and specialty branded pharmaceuticals. Originally incorporated in New York, its headquarters have historically been in Chestnut Ridge, NY. Since 2015, Par Pharmaceutical has operated as a subsidiary of Endo International plc, which has its U.S. headquarters in Malvern, PA. Endo International plc emerged from Chapter 11 bankruptcy in April 2023 and is now a private company. Par Pharmaceutical Inc. operates with approximately 400 employees and an estimated annual revenue of $260.0 million.

The company's operations focus on generic drug products, including high-barrier-to-entry generics, and sterile injectables under the Par Sterile brand. Its portfolio spans numerous therapeutic areas such as anti-inflammatory, cardiovascular, central nervous system, antihypertensive, and antibiotic drugs. Par Pharmaceutical also manufactures active pharmaceutical ingredients (APIs) and has introduced generic versions of prominent drugs including Entocort EC®, Rythmol SR®, and Vasostrict® (a specialty injectable).

According to the provided tracked case data, Par Pharmaceutical Inc. has appeared in one case as a defendant and zero times as a plaintiff. This single tracked case is Otsuka Pharmaceutical Co. Ltd. v. Par Pharmaceutical Inc., where Par was a defendant in the District of Delaware, initiated in 2013. While this specific data indicates a defensive litigation posture, public records also show Par Pharmaceutical Inc. frequently acts as a plaintiff in Hatch-Waxman patent infringement lawsuits, typically to protect its own drug patents against generic manufacturers seeking to introduce competing products. These cases, like the provided one, often take place in the District of Delaware.

Notable context for Par Pharmaceutical includes its acquisition by Endo International plc for $8.05 billion in 2015, significantly expanding Endo's generics segment. The company was also involved in patent litigation concerning Amitiza, which led to a reverse payment antitrust settlement in 2014, with a subsequent antitrust verdict against Takeda Pharmaceuticals in 2026.